Global Multiple Sclerosis Drugs Market to Reach $25.95 Billion by 2025

Strategic Insights -

The global multiple sclerosis (MS) drugs market is projected to grow from $21.27 billion in 2020 to $25.95 billion in 2025, driven by the increasing demand for effective treatments and the introduction of new products. The market is segmented by drug class, distribution channels, and route of administration. The high cost of MS drugs is a significant restraint on market growth.

Multiple sclerosis is an autoimmune disease that affects the brain, spinal cord, and optic nerves, causing problems with muscle control, vision, and other body functions. The disease requires lifelong treatment, which increases the overall cost of treating a patient. To provide better and effective treatment, companies in the multiple sclerosis market are developing new products. In 2019, FDA approved Novartis' Mayzent (siponimod) and EMD Serono's Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug.

The global multiple sclerosis drugs market is dominated by several key players, including Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, and Acorda Therapeutics Inc.

Key Takeaways:

  • The global multiple sclerosis drugs market is expected to grow from $21.27 billion in 2020 to $25.95 billion in 2025, at a compound annual growth rate (CAGR) of 4%.
  • The market is segmented by drug class into immunomodulators, immunosuppressants, interferons, and others.
  • The high cost of MS drugs is a significant restraint on market growth, as it reflects the high cost of treating the disease.
  • Key players in the global multiple sclerosis drugs market include Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, and Acorda Therapeutics Inc.
  • The market is expected to be driven by the introduction of new products and the increasing demand for effective treatments.
  • The support from government and non-government organizations, such as the government of Alberta in Canada, also boosts the growth of the market.
  • The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs.

Statistics:

  • The global multiple sclerosis drugs market was valued at $21.27 billion in 2020.
  • The market is expected to grow to $25.95 billion by 2025, at a CAGR of 4%.
  • The high cost of MS drugs restricts the growth of the market, with the cost of lifelong treatment increasing the overall cost of treating a patient.
  • The government and non-government organizations, such as the government of Alberta in Canada, provide financial support to enhance the quality of life of people affected with multiple sclerosis (MS).
  • The companies in the multiple sclerosis market are developing new products to cater to the rising demands for MS drugs, with Novartis' Mayzent (siponimod) and EMD Serono's Mavenclad (cladribrine) being launched as an easy-to-consume oral drug.

Sources:

  • "Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth and Change to 2030", ResearchAndMarkets.com
  • Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada)
  • ResearchAndMarkets.com's offering
  • M2 Communications
  • M2 PressWIRE